Drugs / CD79b-19 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06026319 | Oct 2023 → Jan 2027 expected | follicular lymphoma, high grade B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma +1 | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD79b-19 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06026319 ↗ |
| Modality | Cell therapy | “CD79b-19 CAR T cells is an investigational treatment that uses a person's own immune cells, called T cells” NCT06026319 ↗ |
| Route | Intravenous | “CD79b-19 CAR T cells will be administered intravenously on day 0 only” NCT06026319 ↗ |
| Target | CD19 | “A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells” NCT06026319 ↗ |
| Target | CD79B | “A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells” NCT06026319 ↗ |